-
1
-
-
2142640813
-
-
1 Rao, Y.K., Fang, S.-H., Tzeng, Y.-M., Bioorg Med Chem, 12, 2004, 2679.
-
(2004)
Bioorg Med Chem
, vol.12
, pp. 2679
-
-
Rao, Y.K.1
Fang, S.-H.2
Tzeng, Y.-M.3
-
2
-
-
9244222261
-
-
2 Sawyers, C., Nature, 432, 2004, 294.
-
(2004)
Nature
, vol.432
, pp. 294
-
-
Sawyers, C.1
-
3
-
-
85014813759
-
-
3 http://www.cancer.org.au/Newsmedia/factsfigures.htm.
-
-
-
-
4
-
-
47149115483
-
-
4 Fadeyi, O.O., Adamson, S.T., Myles, E.L., et al. Bioorg Med Chem Lett, 18, 2008, 4172.
-
(2008)
Bioorg Med Chem Lett
, vol.18
, pp. 4172
-
-
Fadeyi, O.O.1
Adamson, S.T.2
Myles, E.L.3
-
6
-
-
34247363602
-
-
6 Garcia, J.A., Dreicer, R.J., Clin Oncol, 24, 2006, 5545.
-
(2006)
Clin Oncol
, vol.24
, pp. 5545
-
-
Garcia, J.A.1
Dreicer, R.J.2
-
7
-
-
0032724393
-
-
7(a) Dimmock, J.R., Elias, D.W., Beazely, M.A., et al. Curr Med Chem 6 (1999), 1125–1149.
-
(1999)
Curr Med Chem
, vol.6
, pp. 1125-1149
-
-
Dimmock, J.R.1
Elias, D.W.2
Beazely, M.A.3
-
8
-
-
20144367578
-
-
7(b) Go, M.L., Wu, X., Liu, X.L., Curr Med Chem 12 (2005), 483–499.
-
(2005)
Curr Med Chem
, vol.12
, pp. 483-499
-
-
Go, M.L.1
Wu, X.2
Liu, X.L.3
-
9
-
-
57149141162
-
-
7(c) Kontogiorgis, C., Mantzanidou, M., Hadjipavlou-Litina, D., Mini Rev Med Chem, 8, 2008, 1224.
-
(2008)
Mini Rev Med Chem
, vol.8
, pp. 1224
-
-
Kontogiorgis, C.1
Mantzanidou, M.2
Hadjipavlou-Litina, D.3
-
10
-
-
19844379839
-
-
7(d) Agarwal, A., Srivastava, K., Puri, S., et al. Bioorg Med Chem Lett, 15, 2005, 3133.
-
(2005)
Bioorg Med Chem Lett
, vol.15
, pp. 3133
-
-
Agarwal, A.1
Srivastava, K.2
Puri, S.3
-
11
-
-
79958256411
-
-
7(e) Liu, X.-F., Zheng, C.-J., Sun, L.-P., et al. Eur J Med Chem, 46, 2011, 3469.
-
(2011)
Eur J Med Chem
, vol.46
, pp. 3469
-
-
Liu, X.-F.1
Zheng, C.-J.2
Sun, L.-P.3
-
12
-
-
77957017657
-
-
7(f) Zoldakova, M., Kornyei, Z., Brown, A., et al. Biochem Pharmacol, 80, 2010, 1487.
-
(2010)
Biochem Pharmacol
, vol.80
, pp. 1487
-
-
Zoldakova, M.1
Kornyei, Z.2
Brown, A.3
-
13
-
-
77958065694
-
-
7(g) Rao, Y.K., Kao, T.-Y., Ko, J.-L., et al. Bioorg Med Chem Lett, 20, 2010, 6508.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 6508
-
-
Rao, Y.K.1
Kao, T.-Y.2
Ko, J.-L.3
-
14
-
-
72049087235
-
-
7(h) Ducki, S., Rennison, D., Woo, M., et al. Bioorg Med Chem, 17, 2009, 7698.
-
(2009)
Bioorg Med Chem
, vol.17
, pp. 7698
-
-
Ducki, S.1
Rennison, D.2
Woo, M.3
-
15
-
-
84901774750
-
-
7(i) Chauhan, S.S., Singh, A.K., Meena, S., et al. Bioorg Med Chem Lett, 24, 2014, 2820.
-
(2014)
Bioorg Med Chem Lett
, vol.24
, pp. 2820
-
-
Chauhan, S.S.1
Singh, A.K.2
Meena, S.3
-
16
-
-
77955429772
-
-
7(j) Kamal, A., Ramakrishna, G., Raju, P., et al. Bioorg Med Chem Lett, 20, 2010, 4865.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 4865
-
-
Kamal, A.1
Ramakrishna, G.2
Raju, P.3
-
17
-
-
77954316234
-
-
7(k) Kumar, D., Kumar, N.M., Akamatsu, K., et al. Bioorg Med Chem Lett, 20, 2010, 3916.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 3916
-
-
Kumar, D.1
Kumar, N.M.2
Akamatsu, K.3
-
18
-
-
71849101913
-
-
8 Rao, Y.K., Fang, S.-H., Tzeng, Y.-M., Bioorg Med Chem, 17, 2009, 7909.
-
(2009)
Bioorg Med Chem
, vol.17
, pp. 7909
-
-
Rao, Y.K.1
Fang, S.-H.2
Tzeng, Y.-M.3
-
19
-
-
85014870318
-
-
9 Katsori, A.M., Hadjipavlou-Litina, D., Curr Med Chem, 1062, 2009, 16.
-
(2009)
Curr Med Chem
, vol.1062
, pp. 16
-
-
Katsori, A.M.1
Hadjipavlou-Litina, D.2
-
20
-
-
67650759608
-
-
10(a) Awasthi, S.K., Mishra, N., Kumar, B., et al. Med Chem Res 18 (2009), 407–420.
-
(2009)
Med Chem Res
, vol.18
, pp. 407-420
-
-
Awasthi, S.K.1
Mishra, N.2
Kumar, B.3
-
21
-
-
38049156628
-
-
10(b) Lim, S.S., Kim, H.S., Lee, D.U., Bull Korean Chem Soc 28 (2007), 2495–2497.
-
(2007)
Bull Korean Chem Soc
, vol.28
, pp. 2495-2497
-
-
Lim, S.S.1
Kim, H.S.2
Lee, D.U.3
-
22
-
-
77950863523
-
-
11(a) Bandgar, B.P., Patil, S.A., Korbad, B.L., et al. Eur J Med Chem 45 (2010), 2629–2633.
-
(2010)
Eur J Med Chem
, vol.45
, pp. 2629-2633
-
-
Bandgar, B.P.1
Patil, S.A.2
Korbad, B.L.3
-
24
-
-
0003979828
-
Indoles
-
Academic Press London
-
12(a) Sundberg, R.J., Indoles. 1996, Academic Press, London.
-
(1996)
-
-
Sundberg, R.J.1
-
25
-
-
0004061172
-
Heterocyclic Chemistry
-
Blackwell Science Oxford
-
12(b) Joule, J.A., Mills, K., Heterocyclic Chemistry. 2000, Blackwell Science, Oxford.
-
(2000)
-
-
Joule, J.A.1
Mills, K.2
-
26
-
-
33751532464
-
-
E.J. Thomas Thieme Stuttgart
-
13(b) Joule, J.A., Thomas, E.J., (eds.) Science of Synthesis, Vol. 10, 2000, Thieme, Stuttgart.
-
(2000)
Science of Synthesis
, vol.10
-
-
Joule, J.A.1
-
29
-
-
0004061172
-
Heterocyclic Chemistry
-
Stanley Thornes Ltd. Cheltenham
-
13(c) Joule, J.A., Mills, K., Smith, G.F., Heterocyclic Chemistry. 1995, Stanley Thornes Ltd., Cheltenham.
-
(1995)
-
-
Joule, J.A.1
Mills, K.2
Smith, G.F.3
-
30
-
-
0003989782
-
Heterocyclic Chemistry
-
Addison-Wesley Longman Limited Singapore
-
13(d) Gilchrist, T.L., Heterocyclic Chemistry. 1997, Addison-Wesley Longman Limited, Singapore.
-
(1997)
-
-
Gilchrist, T.L.1
-
32
-
-
0017533940
-
-
14(a) Hollenbeak, K. H;. Schmitz, F., J. Lloydia, 1997, 40, 479.
-
(1997)
, vol.40
, pp. 479
-
-
Hollenbeak, K.1
-
33
-
-
85014826985
-
-
14(b) Kondo, K., Nishi, J., Ishibashi, M., et al. J Nat Prod, 1008, 1994, 57.
-
(1994)
J Nat Prod
, vol.1008
, pp. 57
-
-
Kondo, K.1
Nishi, J.2
Ishibashi, M.3
-
34
-
-
66449116601
-
-
14(c) Bialonska, D., Zjawiony, J.K., Marine Drugs, 7, 2009, 166.
-
(2009)
Marine Drugs
, vol.7
, pp. 166
-
-
Bialonska, D.1
Zjawiony, J.K.2
-
35
-
-
64249172315
-
-
15 Brew, C.T., Aronchik, I., Kosco, K., et al. Cancer, 124, 2009, 2294.
-
(2009)
Cancer
, vol.124
, pp. 2294
-
-
Brew, C.T.1
Aronchik, I.2
Kosco, K.3
-
36
-
-
80053261204
-
-
16 Martel-Frachet, V., Kadri, M., Boumendjel, A., et al. Bioorg Med Chem, 19, 2011, 6143.
-
(2011)
Bioorg Med Chem
, vol.19
, pp. 6143
-
-
Martel-Frachet, V.1
Kadri, M.2
Boumendjel, A.3
-
37
-
-
33749609344
-
-
17 Lawrence, N.J., Patterson, R.P., Ooi, L.-L., et al. Bioorg Med Chem Lett, 16, 2006, 5844.
-
(2006)
Bioorg Med Chem Lett
, vol.16
, pp. 5844
-
-
Lawrence, N.J.1
Patterson, R.P.2
Ooi, L.-L.3
-
38
-
-
79952360822
-
-
18 Tarleton, M., Robertson, M.J., Gilbert, J., et al. Med Chem Commun, 2, 2011, 31.
-
(2011)
Med Chem Commun
, vol.2
, pp. 31
-
-
Tarleton, M.1
Robertson, M.J.2
Gilbert, J.3
-
39
-
-
84870886448
-
-
19(a) Tarleton, M., Dyson, L., Gilbert, J., et al. Bioorg Med Chem, 21, 2013, 333.
-
(2013)
Bioorg Med Chem
, vol.21
, pp. 333
-
-
Tarleton, M.1
Dyson, L.2
Gilbert, J.3
-
40
-
-
84908451250
-
-
19(b) Kumar, D., Kumar, N.M., Tantak, M.P., et al. Bioorg Med Chem Lett, 24, 2014, 5170.
-
(2014)
Bioorg Med Chem Lett
, vol.24
, pp. 5170
-
-
Kumar, D.1
Kumar, N.M.2
Tantak, M.P.3
-
41
-
-
84893747286
-
-
20(a) Masand, V.H., Mahajan, D.T., Hadda, T.B., et al. Med Chem Res, 23, 2014, 417.
-
(2014)
Med Chem Res
, vol.23
, pp. 417
-
-
Masand, V.H.1
Mahajan, D.T.2
Hadda, T.B.3
-
42
-
-
77949490562
-
-
20(b) Bandgar, B.P., Patil, S.A., Totre, J.V., et al. Bioorg Med Chem Lett, 20, 2010, 2292.
-
(2010)
Bioorg Med Chem Lett
, vol.20
, pp. 2292
-
-
Bandgar, B.P.1
Patil, S.A.2
Totre, J.V.3
-
43
-
-
84865471611
-
-
20(c) Bandgar, B.P., Adsul, L.K., Lonikar, S.V., et al. J Enzyme Inhib Med Chem, 28, 2013, 593.
-
(2013)
J Enzyme Inhib Med Chem
, vol.28
, pp. 593
-
-
Bandgar, B.P.1
Adsul, L.K.2
Lonikar, S.V.3
-
44
-
-
84858125696
-
-
20(d) Bandgar, B.P., Jalde, S.S., Korbad, B.L., et al. J Enzyme Inhib Med Chem, 27, 2012, 267.
-
(2012)
J Enzyme Inhib Med Chem
, vol.27
, pp. 267
-
-
Bandgar, B.P.1
Jalde, S.S.2
Korbad, B.L.3
-
45
-
-
84921274132
-
-
20(e) Chavan, H.V., Adsul, L.K., Kotmale, A.S., et al. J Enzyme Inhib Med Chem, 30, 2015, 22.
-
(2015)
J Enzyme Inhib Med Chem
, vol.30
, pp. 22
-
-
Chavan, H.V.1
Adsul, L.K.2
Kotmale, A.S.3
-
46
-
-
84881415735
-
-
20(f) Chavan, H.V., Bandgar, B.P., ACS Sustainable Chem Eng, 1, 2013, 929.
-
(2013)
ACS Sustainable Chem Eng
, vol.1
, pp. 929
-
-
Chavan, H.V.1
Bandgar, B.P.2
-
47
-
-
84889680097
-
-
20(g) Jalde, S.S., Chavan, H.V., Adsul, L.K., et al. Synth React Inorg Met-Org Chem, 44, 2014, 623.
-
(2014)
Synth React Inorg Met-Org Chem
, vol.44
, pp. 623
-
-
Jalde, S.S.1
Chavan, H.V.2
Adsul, L.K.3
-
48
-
-
85052265125
-
General procedure for the synthesis of extended conjugated indolyl chalcones (5a–p):To a mixture of 3-(1H-indol-3-yl)-3-oxopropanenitrile2 (1 mmol) in ethanol (15 ml) was added piperidine (0.3 ml) and stirred for 5 min
-
After completion of reaction (monitored by TLC), reaction mixture was poured over crushed ice and acidified with acetic acid. The precipitated solid was filtered, washed with water and oven dried. It was column purified by column chromatography using silica gel mesh size, 100–200 and elution with 10% ethyl acetate in hexane
-
21 General procedure for the synthesis of extended conjugated indolyl chalcones (5a–p):To a mixture of 3-(1H-indol-3-yl)-3-oxopropanenitrile2 (1 mmol) in ethanol (15 ml) was added piperidine (0.3 ml) and stirred for 5 min. Then, added the purified β-chlorovinyl aldehyde 4 (1 mmol) and this mixture was heated to 70 °C for 1–4 h. After completion of reaction (monitored by TLC), reaction mixture was poured over crushed ice and acidified with acetic acid. The precipitated solid was filtered, washed with water and oven dried. It was column purified by column chromatography using silica gel mesh size, 100–200 and elution with 10% ethyl acetate in hexane.
-
Then, added the purified β-chlorovinyl aldehyde 4 (1 mmol) and this mixture was heated to 70 °C for 1–4 h
-
-
-
49
-
-
8744311405
-
-
22 Slatt, J., Romero, I., Bergman, J., Synthesis 16 (2004), 2760–2765.
-
(2004)
Synthesis
, vol.16
, pp. 2760-2765
-
-
Slatt, J.1
Romero, I.2
Bergman, J.3
-
52
-
-
0025341331
-
-
25 Skehan, P., Strong, R., Scadiaro, D., et al. J Natl Cancer Inst 82 (1990), 1107–1112.
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 1107-1112
-
-
Skehan, P.1
Strong, R.2
Scadiaro, D.3
-
53
-
-
85052270401
-
In vitro anti-inflammatory activity by protein denaturation method: The reaction mixture (10 ml) consisted of 0.4 ml of egg albumin (from fresh hen's egg), 5.6 ml of phosphate buffered saline (PBS, pH 6.4) and 4 ml of synthetic derivative (1 mM)
-
Then the mixtures were incubated at (37 °C ± 2) in an incubator for 15 min and then heated at 70 °C for 5 min. After cooling, their absorbance was measured at 660 nm by using vehicle as blank. Diclofenac sodium (1 mM) was used as reference drug and treated similarly for the determination of absorbance. The percentage inhibition of protein denaturation was calculated by using the following formula, % inhibition = 100 × (Vt/Vc − 1); Where, Vt = absorbance of test sample, Vc = absorbance of control
-
26 In vitro anti-inflammatory activity by protein denaturation method: The reaction mixture (10 ml) consisted of 0.4 ml of egg albumin (from fresh hen's egg), 5.6 ml of phosphate buffered saline (PBS, pH 6.4) and 4 ml of synthetic derivative (1 mM). Similar volume of double-distilled water served as control. Then the mixtures were incubated at (37 °C ± 2) in an incubator for 15 min and then heated at 70 °C for 5 min. After cooling, their absorbance was measured at 660 nm by using vehicle as blank. Diclofenac sodium (1 mM) was used as reference drug and treated similarly for the determination of absorbance. The percentage inhibition of protein denaturation was calculated by using the following formula, % inhibition = 100 × (Vt/Vc − 1); Where, Vt = absorbance of test sample, Vc = absorbance of control.
-
Similar volume of double-distilled water served as control
-
-
-
54
-
-
0036672004
-
-
27 Trouba, K.J., Hamadeh, H.K., Amin, R.P., et al. Antioxid Redox Signal 4 (2002), 665–673.
-
(2002)
Antioxid Redox Signal
, vol.4
, pp. 665-673
-
-
Trouba, K.J.1
Hamadeh, H.K.2
Amin, R.P.3
-
56
-
-
85043943202
-
-
29 Velavan, S.; Naghlendran, K.; Mahesh, R.; HazeenaB.V. PHCOGMAG, 1998. ISSN: 0973-1296.
-
(1998)
-
-
-
58
-
-
85043869452
-
24 NO radicals were generated from sodium nitroprusside solution
-
The mixture was incubated at 25 °C for 150 min. After incubation the reaction mixture mixed with 1.0 ml of pre-prepared Griess reagent (1% sulphanilamide, 0.1% naphthyl ethylenediamine dichloride and 2% phosphoric acid). The absorbance was measured at 546 nm and percentage of inhibition was calculated using the same formula as above. The decreasing absorbance indicates a high nitric oxide scavenging activity
-
31 NO radical scavenging activity: NO radical scavenging activity of compounds 5a-p was carried out as per the method. NO radicals were generated from sodium nitroprusside solution. One ml of 10 mM sodium nitroprusside was mixed with 1 ml of 1 mM synthetic compounds in phosphate buffer (0.2 M pH 7.4). The mixture was incubated at 25 °C for 150 min. After incubation the reaction mixture mixed with 1.0 ml of pre-prepared Griess reagent (1% sulphanilamide, 0.1% naphthyl ethylenediamine dichloride and 2% phosphoric acid). The absorbance was measured at 546 nm and percentage of inhibition was calculated using the same formula as above. The decreasing absorbance indicates a high nitric oxide scavenging activity.
-
One ml of 10 mM sodium nitroprusside was mixed with 1 ml of 1 mM synthetic compounds in phosphate buffer (0.2 M pH 7.4)
-
-
-
59
-
-
85043874991
-
Superoxide radical (SOR) scavenging assay: The reaction mixture consisting of 1 ml of nitro blue tetrazolium (NBT) solution (156 mM NBT in phosphate buffer, pH 7.4)
-
The reaction was started by adding 1 ml of phenazine methosulfate (PMS) solution (60 mM PMS in phosphate buffer, pH 7.4) to the mixture. The reaction mixture was incubated at 25 °C for 5 min and the absorbance was measured at 560 nm against blank sample and compared with standards and percentage of inhibition was calculated using the same formula as above. Decreased absorbance of reaction mixture indicated increased SOR scavenging activity
-
32 Superoxide radical (SOR) scavenging assay: The reaction mixture consisting of 1 ml of nitro blue tetrazolium (NBT) solution (156 mM NBT in phosphate buffer, pH 7.4), 1 ml NADH solution (468 mM NADH in phosphate buffer, pH 7.4), and 1 ml of synthetic compound (1 mM) solution was mixed. The reaction was started by adding 1 ml of phenazine methosulfate (PMS) solution (60 mM PMS in phosphate buffer, pH 7.4) to the mixture. The reaction mixture was incubated at 25 °C for 5 min and the absorbance was measured at 560 nm against blank sample and compared with standards and percentage of inhibition was calculated using the same formula as above. Decreased absorbance of reaction mixture indicated increased SOR scavenging activity.
-
1 ml NADH solution (468 mM NADH in phosphate buffer, pH 7.4), and 1 ml of synthetic compound (1 mM) solution was mixed
-
-
-
60
-
-
40149083731
-
-
33 Kumar, R.S., Sivakumar, T., Sundaram, R.S., et al. Pharmacol Therap 5 (2006), 35–41.
-
(2006)
Pharmacol Therap
, vol.5
, pp. 35-41
-
-
Kumar, R.S.1
Sivakumar, T.2
Sundaram, R.S.3
|